The data from the Launch-HTN trial, announced at the 34th European Meeting on Hypertension and Cardiovascular Protection, show that lorundrostat, an aldosterone synthase inhibitor, is a safe and ...

Anumana, a leader in cardiovascular AI, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its pulmonary hypertension (PH) algorithm, an AI-enabled software-as-a-medical-device ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana, a leading AI-driven health technology company and portfolio company of nference, announced a new study that revealed promising results in support of further ...

Secondary hypertension is high blood pressure caused by an underlying health problem, such as kidney disease or hormone imbalances. Unlike primary hypertension, which has no apparent cause, secondary ...

Diagnostic delays in hypertension lead to lower treatment rates and increased cardiovascular risk, with prescription rates decreasing as delays lengthen. Delayed diagnoses correlate with a higher risk ...

Majority of patients with diabetes in case series had uncontrolled hypertension detected ...